Journal
MOLECULAR CANCER
Volume 20, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12943-020-01302-6
Keywords
NK cells; MCL1 inhibitor; BCL2 inhibitor; AML; Immunotherapy
Categories
Funding
- National Natural Science Foundation of China [82000144, 81800140]
- Shanghai Collaborative Innovation Program on Regenerative Medicine and Stem Cell Research [2019CXJQ01]
- Innovative Research Team of High-level Local Universities in Shanghai
- Natural Science Foundation of Shanghai, China [19ZR1432400]
- Guangci Distinguished Young Scholars Training Program [GCQN-2019-B17]
Ask authors/readers for more resources
The proportion of NK cells in the bone marrow could predict the prognosis of ND-AML patients, and combination of MCL1 inhibitor with NK cell-based immunotherapy could effectively improve therapeutic efficiency.
Acute myeloid leukemia (AML) is still incurable due to its heterogeneity and complexity of tumor microenvironment. It is imperative therefore to understand the molecular pathogenesis of AML and identify leukemia-associated biomarkers to formulate effective treatment strategies. Here, we systematically analyzed the clinical characters and natural killer (NK) cells portion in seventy newly-diagnosis (ND) AML patients. We found that the proportion of NK cells in the bone marrow of ND-AML patients could predict the prognosis of patients by analyzing the types and expression abundance of NK related ligands in tumor cells. Furthermore, MCL1 inhibitor but not BCL2 inhibitor combined with NK cell-based immunotherapy could effectively improve the therapeutic efficiency via inhibiting proliferation and inducing apoptosis of AML primary cells as well as cell lines in vitro. There results provide valuable insights that could help for exploring new therapeutic strategies for leukemia treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
